{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:42:15Z","timestamp":1778337735411,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Bruton's tyrosine kinase inhibitor ibrutinib and the B\u2010cell lymphoma 2 anti\u2010apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). However, there is a growing number of patients that relapse after treatment or show refractory disease, thus new targets and agents are still needed. We have previously reported the chemokine receptor CCR7 as a relevant deregulated target in CLL and have developed CAP\u2010100, a novel therapeutic anti\u2010CCR7 antibody that is under evaluation for relapse\/refractory CLL (NCT04704323). While CCR7 expression has been shown to be down\u2010modulated in CLL patients treated with ibrutinib, whether venetoclax acts in a similar manner remains unaddressed. Here, we aimed to document the impact of venetoclax on CCR7 expression in CLL cells, as well as on the pre\u2010clinical activity of CAP\u2010100. To this end, we addressed CCR7 expression by flow cytometry and the antibody efficacy by means of in vitro chemotactic and antibody\u2010dependent cell\u2010mediated cytotoxicity (ADCC) assays. Our data indicate that venetoclax treatment did not significantly modify CCR7 expression pattern nor CAP\u2010100 mechanisms of action. Together, these findings support CAP\u2010100 as an adjuvant therapy to venetoclax that may introduce additional modes of action in CLL therapy.<\/jats:p>","DOI":"10.1002\/hon.3213","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T03:45:09Z","timestamp":1691379909000},"page":"869-876","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the novel therapeutic anti\u2010CCR7 antibody CAP\u2010100 as an add\u2010on therapy in chronic lymphocytic leukemia patients receiving venetoclax"],"prefix":"10.1002","volume":"41","author":[{"given":"Tamara","family":"Mateu\u2010Albero","sequence":"first","affiliation":[{"name":"Immunology Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Marcos\u2010Jimenez","sequence":"additional","affiliation":[{"name":"Immunology Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Delgado\u2010Wicke","sequence":"additional","affiliation":[{"name":"IMMED S.L. Immunological and Medicinal Products  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Terr\u00f3n","sequence":"additional","affiliation":[{"name":"IMMED S.L. Immunological and Medicinal Products  Madrid Spain"},{"name":"Catapult Therapeutics  Lelystad The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Serra","family":"L\u00f3pez\u2010Matencio","sequence":"additional","affiliation":[{"name":"Pharmacy Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Mu\u00f1oz\u2010Calleja","sequence":"additional","affiliation":[{"name":"Immunology Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"},{"name":"Immunology Department Medicine Faculty Universidad Aut\u00f3noma de Madrid  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-9790","authenticated-orcid":false,"given":"Carlos","family":"Cuesta\u2010Mateos","sequence":"additional","affiliation":[{"name":"Immunology Department Hospital Universitario de La Princesa Instituto de Investigaci\u00f3n Sanitaria Instituto Princesa (IIS\u2010IP)  Madrid Spain"},{"name":"IMMED S.L. Immunological and Medicinal Products  Madrid Spain"},{"name":"Catapult Therapeutics  Lelystad The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102018.1.248"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662866"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2297"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.2mr0815\u2010380r"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1917484"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010015\u20101670\u2010z"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201011\u2010390989"},{"key":"e_1_2_11_9_1","volume-title":"Effect of Ibrutinib on CCR7 Expression and Functionality in Chronic Lymphocytic Leukemia and its Implication for the Activity of CAP\u2010100, a Novel Therapeutic Anti\u2010CCR7 Antibody. Cancer Immunology","author":"Mateu\u2010Albero T","year":"2021"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001369"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124560"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188680"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201004\u2010709519"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20101304"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.04.005"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010017\u20103383\u20105"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.316"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2479"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.4.2314"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.c100527200"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010017\u20100066\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201015\u20100986"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201005\u20101346"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119506"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.05.004"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.32106"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.12"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T08:22:03Z","timestamp":1703492523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/hon.3213"],"URL":"https:\/\/doi.org\/10.1002\/hon.3213","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3213\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3213\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3213\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"2023-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}